|
|
| Esperoct® is used to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. |
|
 |
|
|
| It takes real character to live with hemophilia A |
| What's yours? This fun quiz will help you discover what drives you and learn why your personality may matter. |
| Once you've completed the quiz—5 easy questions—you can download a personalized guide. It's a handy way to start a discussion with your doctor about finding a treatment that works for you. |
|
|
|
| Curious to learn about Esperoct®? Keep reading. |
 |
|
| Selected Important Safety Information |
| Who should not use Esperoct®? |
| |
• |
You should not use Esperoct® if you are allergic to factor VIII or
any of the other ingredients of Esperoct® or if you are allergic to
hamster proteins
|
|
|
What is the most important information I need to know about Esperoct®?
|
| |
• |
Do not attempt to do an infusion yourself unless you have been taught how by
your healthcare provider or hemophilia treatment center
|
|
| |
• |
Call your healthcare provider right away or get emergency treatment right away
if you get any signs of an allergic reaction, such as:
hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling
of the face
|
|
|
Please
click here
or scroll below for additional Important Safety Information.
|
|
|
| Introducing Esperoct® |
| With the longest half-life of any recombinant factor VIII product in adultsa, Esperoct® delivers: |
 |
| High factor levels |
| Factor levels at or above 3% for 100% of the time in adults and adolescents who treat prophylactically.b,c |
| Explore Esperoct® > |
 |
| Fewer infusions |
| 50 IU/kg of Esperoct® every four days means 50% fewer infusions if you previously infused every other day or 40% fewer if you infused 3x/week. |
| See how to get started > |
 |
| Bleed control that goes where you go |
| Whatever the situation—prophylaxis, on-demand for sudden bleeds, or use before and after surgery—Esperoct® can see you through. |
| Learn about bleed control > |
|
 |
| Curious if Esperoct® fits in with your treatment personality? |
| Take the quiz! > |
|
|
| aCompared with the half-lives in the Prescribing Information of other EHL recombinant FVIII products. |
| bTrough level goal is typically 1% for prophylaxis. |
| cData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL. |
| We’re here for you at every stage of your treatment journey. |
| With Esperoct®, you can access thorough and personalized support through NovoCare®. We can help with prescription costs, share educational resources, and more.d |
|
|
|
| You may also qualify for the Novo Nordisk free Trial Prescription Program. To see if you are eligible call 1-844-668-6732.e |
| dNovo Nordisk Hemophilia and Rare Bleeding Disorders Copay/Coinsurance Terms and Conditions: Enrolled patients are eligible for up to $12,000 in co-pay/coinsurance assistance per calendar year for each NNI hemophilia or rare bleeding disorder product. Assistance is retroactive to 60 days. Patients must be commercially insured and may not be participating in any government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance. Uninsured, cash-paying patients are not eligible to participate. Patients are eligible to receive co-pay/coinsurance assistance on an annual basis (12 months). Offer good only in the USA, Puerto Rico, Guam, Saipan, and Virgin Islands with participating pharmacies and cannot be redeemed at government-subsidized clinics. Void where taxed, restricted, or prohibited by law. The Savings Card will no longer be valid for residents of Massachusetts. Patient is responsible for complying with any insurance carrier co-payment disclosure requirements, including disclosing any savings received from this program. Re-confirmation of information may be requested periodically to ensure accuracy of data and compliance with terms. This is not an insurance program. Novo Nordisk reserves the right to rescind, revoke, or amend this offer without notice at any time. Non-medication expenses, such as ancillary supplies or administration-related costs, are not eligible. Must have a current prescription for an FDA-approved indication. |
| ePatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance or who are uninsured, may be eligible to receive a limited supply of free product. Patients who participate in any government, state, or federally funded medical or prescription benefit program, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, including patients who participate in a managed Medicaid program or have Medicaid as secondary insurance, are not eligible to receive product support. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product. |
|
| What is Esperoct®? |
| Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery |
| |
• |
Esperoct® is not used to treat von Willebrand Disease |
|
| Important Safety Information (cont’d) |
| What should I tell my healthcare provider before using Esperoct®? |
| |
• |
Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII |
| |
• |
Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct® |
|
| What are the possible side effects of Esperoct®? |
| |
• |
Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion |
|
| Please click here for Prescribing Information. |
| Esperoct® is a prescription medication. |
| You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. |
|
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-877-744-2579. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (e.g. name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
Esperoct® and NovoCare® are registered trademarks of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2021 Novo Nordisk All rights reserved. US20ESP00141 April 2021 |
 |
|
|
|
